242 terminated. 242 Phase 1, 94 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 242 | Terminated 242 |
| Phase 2 | 94 | Terminated 94 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma Vevoctadekin, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Terminated | University of Washington | 1 | 2024-12-18 | 2025-07-29 |
| Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma Descartes-15 - Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Terminated | Cartesian Therapeutics | 4 | 2024-06-19 | 2025-11-24 |
| A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma Alnuctamab, Mezigdomide, Dexamethasone - Multiple Myeloma | Phase 1 | Terminated | Celgene | 4 | 2024-02-27 | 2026-04-21 |
| A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma Forimtamig, Carfilzomib, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Hoffmann-La Roche | 21 | 2023-12-08 | 2026-09-29 |
| Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma IGM-2644 - Multiple Myeloma | Phase 1 | Terminated | IGM Biosciences, Inc. | 4 | 2023-08-29 | 2024-08-01 |
| The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency INZ-701 - Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets | Phase 1 | Terminated | Inozyme Pharma | 9 | 2023-06-25 | 2026-10-15 |
| CART-38 in Adult AML and MM Patients 3x10(6) CART-38 cellls, 7x10(5) CART-38 cells, 7x10(6) CART-38 cells - Acute Myeloid Leukemia (AML), Multiple Myeloma (MM) | Phase 1 | Terminated | University of Pennsylvania | 11 | 2023-05-30 | 2025-06-26 |
| A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) SAR445514 - Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis | Phase 1 | Terminated | Sanofi | 32 | 2023-05-15 | 2026-05-27 |
| A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2) ANV419, Lenalidomide with low-dose dexamethasone, Daratumumab - Multiple Myeloma, Relapsed Cancer | Phase 1 | Terminated | Anaveon AG | 4 | 2023-02-10 | 2024-02-12 |
| A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma Modakafusp Alfa, Daratumumab - Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Teva Branded Pharmaceutical Products R&D LLC | 15 | 2023-01-23 | 2026-01-30 |
| A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Modakafusp alfa, Lenalidomide, Bortezomib - Multiple Myeloma | Phase 1 | Terminated | Teva Branded Pharmaceutical Products R&D LLC | 15 | 2023-01-12 | 2026-01-29 |
| Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple Myeloma Belantamab mafodotin - Multiple Myeloma | Phase 1 | Terminated | M.D. Anderson Cancer Center | 6 | 2023-01-05 | 2025-11-12 |
| Study of VP301 in Patients With Multiple Myeloma, Lymphoma, or Solid Tumors VP301 - Solid Tumors, Adult, Multiple Myeloma | Phase 1 | Terminated | Virtuoso BINco, Inc. | 2 | 2022-11-29 | 2023-09-21 |
| Universal BCMA-targeted LUCAR-B68 Cells in Patients With Relapsed/Refractory Multiple Myeloma LUCAR-B68 cells product - Relapsed/Refractory Multiple Myeloma | Phase 1 | Terminated | Second Affiliated Hospital of Xi'an Jiaotong University | 8 | 2022-11-24 | 2026-06-16 |
| Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma ISB 1442 SC injection escalating doses, ISB 1442 SC injection at RP2D - Relapsed/Refractory Multiple Myeloma | Phase 1 / Phase 2 | Terminated | Ichnos Sciences SA | 29 | 2022-09-27 | 2025-01-17 |
| Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma NMS-03597812, NMS-03597812 + dexamethasone - Multiple Myeloma | Phase 1 | Terminated | Nerviano Medical Sciences | 5 | 2022-09-09 | 2025-06-13 |
| A Study of the Safety, Tolerability and Effectiveness of EZM0414 (IPN60210) Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma EZM0414 - Multiple Myeloma, Refractory, Diffuse Large B-Cell Lymphoma | Phase 1 | Terminated | Epizyme, Inc. | 13 | 2022-05-31 | 2025-06-22 |
| Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma EOS884448, Iberdomide, Dexamethasone - Multiple Myeloma | Phase 1 | Terminated | iTeos Therapeutics | 16 | 2022-05-01 | 2024-10-26 |
| Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease Isatuximab, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 1 | Terminated | Washington University School of Medicine | 1 | 2022-04-01 | 2024-02-09 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL BMF-219 - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Terminated | Biomea Fusion Inc. | 55 | 2022-01-24 | 2025-07-03 |
Showing 20 of 242. Sign in to see all of them.
Multiple Myeloma (211) · Leukemia, Lymphocytic, Chronic, B-Cell (44) · Lymphoma, Non-Hodgkin (40) · Recurrence (40) · Lymphoma (39) · Lymphoma, Large B-Cell, Diffuse (39) · Waldenstrom Macroglobulinemia (37) · Lymphoma, Mantle-Cell (35) · Lymphoma, Follicular (32) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (32) · Lymphoma, B-Cell, Marginal Zone (31) · Neoplasms, Plasma Cell (30) · Hodgkin Disease (29) · Leukemia, Myeloid, Acute (28) · Burkitt Lymphoma (26)
Cardiovascular Diseases (242) · Hemic and Lymphatic Diseases (242) · Vascular Diseases (242) · Hemorrhagic Disorders (241) · Immune System Diseases (239) · Immunoproliferative Disorders (238) · Blood Protein Disorders (237) · Neoplasms by Histologic Type (237) · Paraproteinemias (237) · Lymphoproliferative Disorders (235) · Hematologic Diseases (234) · Neoplasms (216) · Neoplasms, Plasma Cell (208) · Lymphatic Diseases (85)
Dexamethasone (53) · Bortezomib (27) · Lenalidomide (23) · Calcium Dobesilate (17) · Cyclophosphamide (17) · pomalidomide (17) · fludarabine (14) · Rituximab (13) · carfilzomib (11) · daratumumab (11) · Melphalan (10) · Filgrastim (7) · Azacitidine (6) · dexamethasone acetate (6) · fludarabine phosphate (6)
National Cancer Institute (NCI) (15) · Celgene (9) · Amgen (7) · Incyte Corporation (6) · M.D. Anderson Cancer Center (6) · AbbVie (5) · Masonic Cancer Center, University of Minnesota (5) · Cartesian Therapeutics (4) · GlaxoSmithKline (4) · Novartis Pharmaceuticals (4) · University of Pennsylvania (4) · Barbara Ann Karmanos Cancer Institute (3) · Gilead Sciences (3) · Mayo Clinic (3) · Seagen Inc. (3)
United States (211) · Spain (31) · France (23) · Australia (20) · Italy (17) · Japan (15) · Canada (14) · Germany (12) · South Korea (11) · Israel (9) · United Kingdom (8) · Greece (7) · Belgium (6) · Czechia (6) · China (5)
Roger Strair, MD, PhD (3) · Abhinav Deol, M.D. (2) · Ajay Gopal (2) · Claudio G. Brunstein, MD, PhD (2) · Edward Stadtmauer, MD (2) · Fabio Ciceri, MD (2) · Fred Zheng, M.D. (2)
PMID 31215818, PMID 31527168, PMID 34398557, PMID 18297527, PMID 22080968, PMID 23256542, PMID 23400739, PMID 24241210, PMID 25655379, PMID 26139427, PMID 26384354, PMID 28140719, PMID 28261656, PMID 28461396, PMID 29141948, PMID 30190454, PMID 30962222, PMID 31090915, PMID 31229804, PMID 31443741, PMID 31471376, PMID 31558469, PMID 31969330, PMID 32029687, PMID 32238921, PMID 32898244, PMID 33171487, PMID 33451977, PMID 33554732, PMID 33792221, PMID 34045234, PMID 34187739, PMID 34289017, PMID 34951522, PMID 35176457, PMID 35285015, PMID 36051045, PMID 36273822, PMID 36452492, PMID 36460794, PMID 36534160, PMID 36650020, PMID 36841672, PMID 37024520, PMID 37290996, PMID 37399355, PMID 37414012, PMID 37646702, PMID 37794590, PMID 37880389
2017 (4), 2018 (4), 2023 (4), 2019 (3), P30CA015083 (3), P30CA072720 (3), 2016 (2), P30CA043703 (2), U01CA069912 (2), U01CA076576 (2), 2008 (1), 2014 (1), 2015 (1), N01CM00070 (1), N01CM62203 (1)